Led · Seed · Jul 2024

Sqill offers an AI-based, all-in-one content creation platform available on iOS and Android, with an AI-powered video editor that simplifies creation, editing, and sharing of branded social content within minutes. The product supports real-time collaboration for social media teams and manages the full production-to-publishing workflow. Sqill currently serves dozens of clients across Portugal, Spain, Brazil, and the USA, including brands such as FC Porto, Worten, and L’Oréal. The company is incubated at Startup Lisboa and Instituto Pedro Nunes and has been iterating closely with initial clients to optimize the product. With the new funding, Sqill plans to consolidate its presence in the US by opening an office in Austin, Texas, expand its team (recruiting in Portugal and the US), and grow into sports, retail, and corporate verticals. The team has stated intentions to forge partnerships with federations, leagues, clubs, and other sports organizations as part of its expansion.

Participated · Equity · Jul 2024

Indie Campers operates a digital platform and network that lets customers rent customizable recreational vehicles across more than 70 locations. Founded in 2013 and headquartered in Lisbon, the company runs a fleet of over 7,000 RVs across three continents and more than twenty countries. It employs over 500 people worldwide and has been profitable since inception. The company plans to use new capital to invest in technological development of its digital platform, streamline operations, and enhance customer experience. Indie Campers also intends to expand its global footprint, offer new products and services, and accelerate recruitment across product, tech, data, and marketing to support growth.

Participated · Series B · Apr 2024

CryoTherapeutics has developed an intravascular catheter system that delivers cryoenergy at approximately –10° to –20°C via a console-controlled cooling agent to stabilise high-risk coronary plaque and potentially prevent heart attacks. The company has completed first-in-human studies with follow-up and reports promising early data on safety and feasibility. CoreAlst served as the corelab involved in analysis of the clinical data, and the firm plans to present early human results at CRT in Washington DC and at EuroPCR in Paris. Proceeds from its recent fundraise will support additional clinical evaluation of the technology and the development of a next-generation catheter system for advanced clinical studies and early commercialisation. CryoTherapeutics said it will also use funding to expand its team in Liège. The company was founded by John Yianni, who is a board member of several medical device companies and a partner at Earlybird Venture Capital Health Fund. CryoTherapeutics develops a proprietary intravascular cryotherapy catheter that delivers sub-zero temperatures at its tip to treat inflamed areas of the coronary artery and stabilise atherosclerotic lesions. The company is focused on demonstrating clinical benefit and early-stage commercialization of this cryo-energy technology in cardiovascular disease. It plans to leverage recent imaging breakthroughs to target vulnerable plaques and is commencing its first clinical study focused on treating this disease. Proceeds from the latest financing will fund that clinical study and support development of a next-generation cryotherapy system aimed at commercial launch. The company also intends to expand its team and local partnerships in the Walloon region as it advances development. CryoTherapeutics was established in December 2009 in Germany and located in Awans (Liège) in 2019. CryoTherapeutics develops a proprietary cryotherapy system—an intravascular catheter that delivers sub-zero temperatures at its tip to treat inflamed areas of the coronary artery. The technology aims to stabilize lesions that might rupture and cause heart attacks, positioning the product for treatment of coronary artery disease. The company is focused on development, demonstration of clinical benefit, and early-stage commercialization. It intends to use the €7m Series B funds for clinical activities, further R&D, talent acquisition, international growth and to establish operations at a new facility in Awans, Belgium. Financing came as a mix of equity, debt and grants, including non-dilutive cash advances from the Walloon region (DG06); investors include Noshaq, Peppermint Venture Partners, Creathor Ventures and Getz Brothers. CryoTherapeutics was established in December 2009 and is led by CEO John Yianni. CryoTherapeutics is developing a proprietary cryotherapy system delivered via catheter for treatment of coronary artery disease, including acute coronary syndromes and myocardial infarction. The approach aims in many patients to avoid the use of intravascular stents or scaffolds, thereby maintaining vascular function in the treated vessel. The company intends to advance its catheter-based system into a clinical trial with the goal of achieving CE-mark market approval in Europe. In July 2016 it raised €5.2m in a Series B financing to support that clinical development. The round was led by Creathor Venture and included existing investors. CryoTherapeutics was established in December 2009 by Dr. John Yianni (CEO) and Dr. Maurice Buchbinder (CMO) and is based in Potsdam, Germany. CryoTherapeutics develops a proprietary catheter-based cryotherapy system intended to treat coronary artery disease and prevent heart attacks. The system uses cryoenergy and is designed for use by interventional cardiologists during acute care. The company's initial objective is to demonstrate the clinical benefit of the catheter-based approach in treating heart attack patients. CryoTherapeutics completed an extension to its Series A financing, bringing the total of the round to €6.5m. Established in December 2009 and based in Cologne, Germany, the company is advancing its device toward clinical demonstration. Management is led by Maurice Buchbinder, MD, Chief Medical Officer, and John Yianni, PhD, Managing Director.

Led · Equity · Feb 2024

Weezie is a Porto-based SaaS company that provides a digital management platform for fiber-optic networks, integrating planning, execution, control and management into a single ecosystem. The software was created to digitize and automate conventional fiber network management practices and reduce working time versus traditional methods. Weezie reports having helped clients deliver fiber to more than 60 million homes and operates in six geographic markets, with entries into the United States and Mexico in 2023. The company is focused on R&D and product implementation to improve operator workflows and customer experience. Weezie is actively recruiting across technical, commercial and support roles to strengthen internal operations. Founded in 2018, the company emphasizes continued internationalization and product-led growth.

Led · Seed · Jan 2024

Full Venue leverages AI to transform how sports and events organizations monetize their audiences, emphasizing simplicity and integration with marketing channels. The company has established partnerships with Hype Sports Innovation, EIT Digital, Startup Bootcamp and APEX. It operates in seven geographical markets: Portugal, Spain, the UK, Finland, Belgium, Romania and Chile. Led by CEO Tiago Costa Rocha and COO Marcos Castro, Full Venue focuses on expanding commercial reach and product adoption. The company raised €2M in Seed funding and intends to use the proceeds to expand operations and its business reach. No revenue or user metrics were disclosed in the article.